Biocon Biologics to Acquire Viatris’ Biosimilars Assets in USD 3.335 billion
Biocon Biologics Limited’s (BBL) acquisition of Viatris’ rights in biosimilars assets, creates a unique global, vertically ...
Read moreBiocon Biologics Limited’s (BBL) acquisition of Viatris’ rights in biosimilars assets, creates a unique global, vertically ...
Read moreBiocon Pharma Limited, a subsidiary of Biocon Limited, received approval of its ANDA for Posaconazole Delayed-Release ...
Read moreBiocon appointed Mr. Indranil Sen as the Chief Financial Officer and Key Managerial Personnel of the ...
Read moreBiocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated ...
Read moreBiocon Biologics Ltd., announced today that it has been awarded with the 2021 Facility of the ...
Read moreKiran Mazumdar-Shaw has been appointed to the Board of Trustees of Memorial Sloan Kettering Cancer Center ...
Read moreBiocon Biologics Ltd., a subsidiary of Biocon Ltd, has announced that Abevmy® 100 & 400 mg, ...
Read moreBiocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good ...
Read moreBiocon Ltd today announced a partnership between Biocon Pharma Limited, a wholly owned subsidiary of Biocon ...
Read moreAddress: | Pharma Reg News, First floor, Shop no.1 , Plot no 241,242, Near Fire station, GIDC, Ankleshwar, Gujarat - 393002. |
Phone: | +91 8511586232, +91 9029066605 |
Email: | author@pharmaregnews.com |
© 2021 - Pharmaregnews.com. Developed by YESWEUS.
© 2021 - Pharmaregnews.com. Developed by YESWEUS.